Theriva Biologics Files 8-K on Financials
Ticker: TOVX · Form: 8-K · Filed: Mar 6, 2025 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | Mar 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, disclosure
Related Tickers: THRX
TL;DR
Theriva Biologics (THRX) filed an 8-K on March 6, 2025, detailing its financial condition and operations.
AI Summary
Theriva Biologics, Inc. filed an 8-K on March 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. The company was formerly known as Synthetic Biologics, Inc. and is incorporated in Nevada.
Why It Matters
This 8-K filing provides investors with crucial updates on Theriva Biologics' financial health and operational performance, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not inherently present new risks.
Key Players & Entities
- Theriva Biologics, Inc. (company) — Registrant
- Synthetic Biologics, Inc. (company) — Former company name
- March 6, 2025 (date) — Date of report
- Nevada (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Theriva Biologics, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on March 6, 2025.
What was Theriva Biologics, Inc. formerly known as?
Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc.
In which state is Theriva Biologics, Inc. incorporated?
Theriva Biologics, Inc. is incorporated in Nevada.
What is the company's Standard Industrial Classification (SIC) code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 6, 2025 regarding Theriva Biologics, Inc. (TOVX).